MarkGabrielLebwohlMD

Dean for Clinical Therapeutics, Professor and Chairman Emeritus of Dermatology, Icahn School of Medicine at Mount Sinai

Overview of Dr. Lebwohl

Dr. Mark Lebwohl is a dermatologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, New York Eye and Ear Infirmary of Mount Sinai, and Mount Sinai Brooklyn. He received his medical degree from Harvard Medical School and has been in practice 45 years. He is one of 54 doctors at Mount Sinai Brooklyn and one of 26 doctors at New York Eye and Ear Infirmary of Mount Sinai who specialize in Dermatology. He has more than 100 publications and over 500 citings.

Office
5 e 98 st
New York, NY 10029
Book by Phone+1(205) 850-7825
Is this information wrong?

Education & Training

Icahn School of Medicine at Mount SinaiResidency, Dermatology, 1981 - 1983
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1978 - 1981
Harvard Medical SchoolClass of 1978

Certifications & Licensure

NY State Medical License 1980 - 2025
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Gold Medal American Academy of Dermatology, 2022
Top MD Consumers Checkbook
Whos Who in Medicine and Healthcare Marquis Whos Who
Super Doctor SuperDoctors.com
Fellow (FAAD) American Academy of Dermatology
Join now to see all

Clinical Trials

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Start of enrollment: 2010 Sep 01
Completed
Phase 3
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) Start of enrollment: 2012 Aug 01
Completed
Phase 2
LEO 90100 in the Treatment of Psoriasis Vulgaris Start of enrollment: 2012 May 01
Completed
Phase 2
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp Start of enrollment: 2013 Mar 01
Completed
Phase 1
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2013 Mar 01
Completed
Phase 1
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients Start of enrollment: 2013 May 01
Completed
Phase 2
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis Start of enrollment: 2013 Jun 01
Completed
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Start of enrollment: 2014 Mar 19
Completed
Phase 2
Reduction of Pain Caused by Biologic Drugs in Psoriasis Start of enrollment: 2014 May 01
Completed
Not Applicable
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles Start of enrollment: 2014 Jun 01
Terminated
Phase 4
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 2
Treatment of Actinic Keratoses (AK) on the Face Start of enrollment: 2015 Mar 01
Completed
Phase 1
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris Start of enrollment: 2017 Feb 15
Completed
Phase 3
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Start of enrollment: 2017 Apr 14
Completed
Phase 2
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Start of enrollment: 2019 May 27
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.
Sima, A., Janak, J., Patel, M., Photowala, H., Garg, V., Strober, B., Duffin, K., Lebwohl, M., Bagel, J.> ;The Journal of Dermatological Treatment. 2024 Dec 1
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B Gottlieb, Mark Lebwohl, Joseph F Merola, Bruce Strobe...> ;Journal of the American Academy of Dermatology. 2024 Apr 6
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial.
Linda Stein Gold, David N Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura K Ferris, Melinda J Gooderham, H Chih-Ho Hong, Steven E Kempers, Leon H Kircik, Mark Le...> ;Journal of the American Academy of Dermatology. 2024 Mar 29
Executive Summary: From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psor...
Warren A James, Angela L Rosenberg, Jashin J Wu, Sylvia Hsu, April Armstrong, Elizabeth B Wallace, Lara Wine Lee, Joseph Merola, Sergio Schwartzman, Dafna Gladman, Cli...> ;Journal of the American Academy of Dermatology. 2024 Mar 16
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Bruce Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata ...> ;Journal of the European Academy of Dermatology and Venereology. 2024 Mar 7
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B Gottlieb, Philip J Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa ...> ;Dermatology and Therapy. 2024 Mar 1
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
Andrew Blauvelt, April Armstrong, Joseph F Merola, Bruce Strober, Dirk de Cuyper, Luke Peterson, Owen Davies, Jeffrey L Stark, Mark Lebwohl> ;Journal of the American Academy of Dermatology. 2024 Mar 4
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Shah, M., Crowley, J., Gordon, K., Shahriari, M., Burshtein, J., Zakria, D., Lockshin, B., Merola, J., Korman, N., Chovatiya, R., Kalb, R., Lebwohl, M.> ;Dermatology and Therapy. 2024 Feb 1
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with genera...
Burden, A., Bissonnette, R., Anatchkova, M., Budhiarso, I., Skalicky, A., Liberato, A., Hu, N., Thoma, C., Gloede, T., Kohlmann, T., Lebwohl, M.> ;Journal of the European Academy of Dermatology and Venereology. 2024 Feb 9
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the Nat...
Chat, V., Ellebrecht, C., Kingston, P., Gondo, G., Bell, S., Cordoro, K., Desai, S., Duffin, K., Feldman, S., Garg, A., Gelfand, J., Gladman, D., Green, L., Gudjonsson...> ;Journal of the American Academy of Dermatology. 2024 Feb 7
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
Warren, R., Imafuku, S., Paul, C., Szepietowski, J., Spelman, L., Passeron, T., Vritzali, E., Napoli, A., Kisa, R., Buck, A., Banerjee, S., Thaçi, D., Lebwohl, M., Sof...> ;The British Journal of Dermatology. 2024 Jan 16
1 citations
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F Merola, Mark Lebwohl, Akimichi Morita, Jacek C Szepietowski, Jo Lambert, Lauren Hippeli, Elizabeth ...> ;Journal of the American Academy of Dermatology. 2024 Apr 1
Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis.
Sophie Guénin, Elizabeth Andrews, Mark G Lebwohl> ;The British Journal of Dermatology. 2024 Feb 16
Nail psoriasis and nail lichen planus: Updates on diagnosis and management.
Jonathan K Hwang, Chander Grover, Matilde Iorizzo, Mark G Lebwohl, Bianca M Piraccini, Dimitris G Rigopoulos, Shari R Lipner> ;Journal of the American Academy of Dermatology. 2024 Mar 1
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Owen Davies, Diamant ...> ;The British Journal of Dermatology. 2024 Mar 15
2 citations
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Bruce Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D Chakravarty...> ;Drug Safety. 2024 Jan 1
2 citations
Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation.
April W Armstrong, Carly A Elston, Boni E Elewski, Laura K Ferris, Alice B Gottlieb, Mark G Lebwohl, , Merola, J. F., Merola, J. F., Merola, J. F.> ;Journal of the American Academy of Dermatology. 2024 Apr 1
1 citations
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase 3 studies.
Mark Lebwohl, Lars Iversen, Liv Eidsmo, James G Krueger, Mayte Suárez-Fariñas, Lewis Tomalin, Frank Kolbinger, Ruquan You, Marina Milutinovic> ;Clinical and Experimental Dermatology. 2023 Oct 11
Development of the Generalized Pustular Psoriasis Clinical Assessment Tool.
Amit Garg, Megan H Noe, Milan J Anadkat, April Armstrong, Tina Bhutani, Aaron Farberg, George Han, Jason E Hawkes, Mark Lebwohl, Sergey Rekhtman, Eingun J Song, Andrew...> ;Journal of the American Academy of Dermatology. 2024 Jan 1
Advances in biologic therapy of psoriasis.
Mark Lebwohl> ;Journal of the European Academy of Dermatology and Venereology. 2023 Sep 1
1 citations
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial u...
Kim A Papp, Andrew Blauvelt, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, Ahmad Z Amin, Jie Liu, Tianshuang Wu, Tofial Azam, Vassilis Stakias, Ram...> ;Journal of the American Academy of Dermatology. 2023 Dec 1
Bexarotene use in refractory Darier's disease.
Mark Lebwohl, Sophie Guenin> ;International Journal of Dermatology. 2023 Nov 1
1 citations
Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials.
Saxon D Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl> ;Dermatology and Therapy. 2023 Aug 1
7 citations
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Andrew Blauvelt, Andrea Chiricozzi, Benjamin D Ehst, Mark G Lebwohl> ;Advances in Therapy. 2023 Aug 1
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomise...
Paolo Gisondi, Alice B Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M López Pinto, Nicola Til...> ;Dermatology and Therapy. 2023 Jun 1
Join now to see all

Lectures

Dilemmas and Challenges in Skin Cancer Therapies and Management
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Press Mentions

Brodalumab: 4-Year US Pharmacovigilance ReportMarch 14th, 2023
Psoriasis Drugs for Patients with Cancer, Obesity, Psoriatic ArthritisFebruary 18th, 2023
Notalgia Paresthetica: Difelikefalin Helps Upper-Back Itch, but with Side EffectsFebruary 13th, 2023
Join now to see all